Conditions: Social Anxiety Disorder
Keywords: Social Anxiety Disorder Social Phobia SAD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 63
Healthy volunteers: no

Brief summary:
This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).

Detailed description:
Social Anxiety Disorder (SAD) is recognized as a prevalent, chronic and disabling condition. Lifetime prevalence has been estimated at 13% in the National Comorbidity Survey. There is good reason to think that Pristiq® would be effective in Social Anxiety Disorder. Effexor XR, which is mechanistically similar to Pristiq®, was found effective for subjects with Generalized Social Anxiety Disorder in all five of the placebo controlled trials in which it was studied.

Arms:
arm 1: Flexible dose, 50-100mg QD arm 2: Matching placebo

Interventions: intervention 1: Pristiq intervention 2: Placebo
Intervention descriptions: intervention 1: Flexible dose, 50-100mg QD, for 12 weeks. intervention 2: Matching placebo, taken QD for 12 weeks.

Protocol document: